Innovative Approaches for Onychomycosis Treatment: An Insight Into Natural Remedies and Novel Pharmaceutical Formulations
Abstract
Onychomycosis, commonly referred to as nail fungus, is a persistent and difficult-to-treat condition that affects both toes and fingernails. Even though traditional treatments such as antifungal medications and topical ointments are effective in some cases, they are often associated with significant side effects and a high recurrence rate. There has been a growing interest in alternative and complementary treatments in recent years, including natural remedies and new pharmaceutical formulations, which are becoming increasingly popular. This review aims to explore the current state of knowledge surrounding onychomycosis treatment and its challenges, with a particular focus on the benefits and limitations of the current therapeutic options. Also, light is shed on the prospects available as treatment options.
References
Piraccini BM, Alessandrini A. Onychomycosis: a review. J Fungi. 2015 Mar 27;1(1):30-43. doi: 10.3390/jof1010030.
Thomas J, Jacobson GA, Narkowicz CK, Peterson GM, Burnet H, Sharpe C. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther. 2010 Oct;35(5):497-519. doi: 10.1111/j.1365-2710.2009.01107.x.
Vanam HP, Rao PN, Mohanram K, Yegneswaran PP, Rudramurthy SP. Distal lateral subungual onychomycosis owing to Tritirachium oryzae: a bystander or invader?. Mycopathologia. 2018 Apr;183(2):459-63. doi: 10.1007/s11046-017-0226-5.
Kaynak E, Göktay F, Güneş P, Sayman E, Turan D, Baygül A, et al. The role of dermoscopy in the diagnosis of distal lateral subungual onychomycosis. Arch Dermatol Res. 2018 Jan;310:57-69. doi: 10.1007/s00403-017-1796-2.
Baran R, Hay R, Perrin C. Superficial white onychomycosis revisited. J Eur Acad Dermatol Venereol. 2004 Sep;18(5):569-71. doi: 10.1111/j.1468-3083.2004.01015.x.
Piraccini BM, Tosti A. White superficial onychomycosis: epidemiological, clinical, and pathological study of 79 patients. Arch Dermatol. 2004 Jun 1;140(6):696-701. doi: 10.1001/archderm.140.6.696.
Phaitoonwattanakij S, Leeyaphan C, Bunyaratavej S, Chinhiran K. Trichophyton erinacei onychomycosis: The first to evidence a proximal subungual onychomycosis pattern. Case Rep Dermatol. 2019 Sep 2;11(2):198-203. doi: 10.1159/000501424.
Borgohain P, Barua P, Dutta PJ, Shaw D, Rudramurthy SM. Onychomycosis associated with superficial skin infection due to Aspergillus sydowii in an immunocompromised patient. Mycopathologia. 2019 Oct;184(5):683-9. doi: 10.1007/s11046-019-00383-2.
Tosti A, Baran R, Piraccini BM, Fanti PA. Endonyx onychomycosis: a new modality of nail invasion by dermatophytes. Acta Derm Venereol. 1999 Jan 1;79(1):52-3. doi: 10.1080/000155599750011714.
Souza LW, Souza SV, Botelho AC. Endonyx toenail onychomycosis caused by Trichophyton rubrum: treatment with photodynamic therapy based on methylene blue dye. An Bras Dermatol. 2013 Nov;88:1019-21. doi: 10.1590/abd1806-4841.20132180.
Bhattacharjee B, Dey N, Barman D, Karmakar A, Ahmed N. Understanding the drug delivery through nails: a comprehensive review. J Drug Deliv Ther. 2021 Jul 15;11(4):116-31. doi: 10.22270/jddt.v11i4.4941.
Kowalczyk AP, Green KJ. Structure, function, and regulation of desmosomes. Prog Mol Biol Transl Sci. 2013 Jan 1;116:95-118. doi: 10.1016/B978-0-12-394311-8.00005-4.
Kobayashi Y, Komatsu T, Sumi M, Numajiri S, Miyamoto M, Kobayashi D, et al. In vitro permeation of several drugs through the human nail plate: relationship between physicochemical properties and nail permeability of drugs. Eur J Pharm Sci. 2004 Mar 1;21(4):471-7. doi: 10.1016/j.ejps.2003.11.008.
Baswan S, Kasting GB, Li SK, Wickett R, Adams B, Eurich S, et al. Understanding the formidable nail barrier: A review of the nail microstructure, composition and diseases. Mycoses. 2017 May;60(5):284-95. doi: 10.1111/myc.12592.
McAuley WJ, Jones SA, Traynor MJ, Guesné S, Murdan S, Brown MB. An investigation of how fungal infection influences drug penetration through onychomycosis patient’s nail plates. Eur J Pharm Biopharm. 2016 May 1;102:178-84. doi: 10.1016/j.ejpb.2016.03.008.
Walters KA, Flynn GL, Marvel JR. Physicochemical characterization of the human nail: solvent effects on the permeation of homologous alcohols. J Phar Pharmacol. 1985 Nov;37(11):771-5. doi: 10.1111/j.2042-7158.1985.tb04966.x.
Chen K, Puri V, Michniak-Kohn B. Iontophoresis to overcome the challenge of nail permeation: considerations and optimizations for successful ungual drug delivery. AAPS journal. 2021 Jan;23:1-5. doi: 10.1208/s12248-020-00552-y.
Amichai B, Nitzan B, Mosckovitz R, Shemer A. Iontophoretic delivery of terbinafine in onychomycosis: a preliminary study. Br J Dermatol. 2010 Jan 1;162(1):46-50. doi: 10.1111/j.1365-2133.2009.09414.x.
Lipner SR, Scher RK. Onychomycosis: Treatment and prevention of recurrence. J Am Acad Dermatol. 2019 Apr 1;80(4):853-67. doi: 10.1016/j.jaad.2018.05.1260.
Gupta AK, Mays RR, Versteeg SG, Shear NH, Friedlander SF. Onychomycosis in children: Safety and efficacy of antifungal agents. Pediatr Dermatol. 2018 Sep;35(5):552-9. doi: 10.1111/pde.13561.
Manevitch Z, Lev D, Hochberg M, Palhan M, Lewis A, Enk CD. Direct antifungal effect of femtosecond laser on Trichophyton rubrum onychomycosis. JPPA. 2010 Mar;86(2):476-9. doi: 10.1111/j.1751-1097.2009.00672.x.
Gupta AK, Drummond-Main C, Cooper EA, Brintnell W, Piraccini BM, Tosti A. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. JAAD. 2012 Mar 1;66(3):494-502. doi: 10.1016/j.jaad.2011.02.038.
Ameen M, Lear JT, Madan V, Mohd Mustapa MF, Richardson M, Hughes JR, et al. British Association of Dermatologists' guidelines for the management of onychomycosis 2014. BJD. 2014 Nov 1;171(5):937-58. doi: 10.1111/bjd.13358.
Piraccini BM, Iorizzo M, Lencastre A, Nenoff P, Rigopoulos D. Ciclopirox hydroxypropyl chitosan (HPCH) nail lacquer: a review of its use in onychomycosis. J Dermatol Treat. 2020 Oct;10:917-29. doi: 10.1007/s13555-020-00420-9.
Aslam R, Hussain T, Yousaf AM, Ghori MU, Khan IU, Rizvi SA, et al. Onychomycosis: current understanding and strategies for enhancing drug delivery into human nail tissue. Curr. Drug Abuse Rev. 2021 Mar 1;13(1):25-35. doi: 10.2174/2589977512666200731171505.
Cook-Bolden FE, Lin T. Efinaconazole solution 10% for treatment of toenail onychomycosis in Latino patients. Cutis. 2017 Apr 1;99(4):286-9. PMID: 28492600.
FDA OKs First Topical Triazole Antifungal for Onychomycosis [Internet]. [Cited: 26-Jan-2023]. Available from: https://www.medscape.com/viewarticle/826480.
Elewski BE, Rich P, Pollak R, Pariser DM, Watanabe S, Senda H, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. JAAD. 2013 Apr 1;68(4):600-8. doi: 10.1016/j.jaad.2012.10.013.
Gupta AK, Hall S, Zane LT, Lipner SR, Rich P. Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies. J Dermatol Treat. 2018 Jan 2;29(1):44-8. doi: 10.1080/09546634.2017.1329510.
Elewski B, Zane L, Rich P, Aly R, Gonzalez Soto R. Pivotal phase III safety and efficacy results of tavaborole (AN2690), a novel boron-based molecule for the topical treatment of toenail onychomycosis. JAAD. 2014 May;70(5):AB91-AB91. doi: 10.1016/j.jaad.2014.01.379.
Piraccini BM, Sisti A, Tosti A. Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. JAAD. 2010 Mar 1;62(3):411-4. doi: 10.1016/j.jaad.2009.04.062.
American Academy of Dermatology | Choosing Wisely [Internet]. [Cited: 26-Jan-2023]. Availablefrom: https://www.choosingwisely.org/societies/american-academy-of-dermatology/.
Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. JAAD. 2000 Feb 1;42(2):217-24. doi: 10.1016/S0190-9622(00)90129-4.
Tosti A, Piraccini BM, Lorenzi S, Iorizzo M. Treatment of nondermatophyte mold and Candida onychomycosis. Dermatol Clin. 2003 Jul 1;21(3):491-7. doi: 10.1016/S0733-8635(03)00036-6.
Kreijkamp‐Kaspers S, Hawke K, Guo L, Kerin G, Bell‐Syer SE, Magin P, et al. Oral antifungal medication for toenail onychomycosis. Cochrane Database Syst Rev. 2017 Jul 14;7(7):CD010031. doi: 10.1002/14651858.CD010031.pub2.
Sigurgeirsson B, van Rossem K, Malahias S, Raterink K. A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. JAAD. 2013 Sep 1;69(3):416-25. doi: 10.1016/j.jaad.2013.03.021.
Gupta AK, Studholme C. Novel investigational therapies for onychomycosis: an update. EOIDER. 2016 Mar 3;25(3):297-305. doi: 10.1517/13543784.2016.1142529.
Landsman AS, Robbins AH, Angelini PF, Wu CC, Cook J, Oster M, et al. Treatment of mild, moderate, and severe onychomycosis using 870-and 930-nm light exposure. JAMA. 2010 May 1;100(3):166-77. doi: 10.7547/1000166.
Hollmig ST, Rahman Z, Henderson MT, Rotatori RM, Gladstone H, Tang JY. Lack of efficacy with 1064-nm neodymium: yttrium-aluminum-garnet laser for the treatment of onychomycosis: a randomized, controlled trial. J Am Acad Dermatol. 2014 May 1;70(5):911-7. doi: 10.1016/j.jaad.2013.12.024.
Karsai S, Jäger M, Oesterhelt A, Weiss C, Schneider SW, Jünger M, et al. Treating onychomycosis with the short‐pulsed 1064‐nm‐Nd: YAG laser: results of a prospective randomized controlled trial. J Eur Acad Dermatol Venereol. 2017 Jan;31(1):175-80. doi: 10.1111/jdv.13798.
Gupta AK, Paquet M, Simpson FC. Therapies for the treatment of onychomycosis. Clin Dermatol. 2013 Sep 1;31(5):544-54.https://doi.org/10.1016/j.clindermatol.2013.06.011.
Amichai B, Nitzan B, Mosckovitz R, Shemer A. Iontophoretic delivery of terbinafine in onychomycosis: a preliminary study. Br J Dermatol. 2010 Jan 1;162(1):46-50. doi: 10.1111/j.1365-2133.2009.09414.x.
Amichai B, Mosckovitz R, Trau H, Sholto O, Ben-Yaakov S, Royz M, et al. Iontophoretic terbinafine HCL 1.0% delivery across porcine and human nails. Mycopathologia. 2010 May;169:343-9. doi: 10.1007/s11046-009-9265-x.
Cowan MM. Plant products as antimicrobial agents. Clin Microbiol Rev. 1999 Oct 1;12(4):564-82. doi: 10.1128/cmr.12.4.564.
Low WL, Kenward K, Britland ST, Amin MC, Martin C. Essential oils and metal ions as alternative antimicrobial agents: a focus on tea tree oil and silver. Int Wound J. 2017 Apr;14(2):369-84. doi: 10.1111/iwj.12611.
Tea tree oil for onychomycosis: does it work? [Internet]. [Cited: 27-Jan-2023]. Available from: https://www.hmpgloballearningnetwork.com/site/podiatry/blogged/tea-tree-oil-onychomycosis-does-it-work.
Hammer K, Carson CF, Riley TV. Antifungal activity of the components of Melaleuca alternifolia (tea tree) oil. J Appl Microbiol. 2003 Oct 1;95(4):853-60. doi: 10.1046/j.1365-2672.2003.02059.x.
Ramage G, Milligan S, Lappin DF, Sherry L, Sweeney P, Williams C, et al. Antifungal, cytotoxic, and immunomodulatory properties of tea tree oil and its derivative components: potential role in management of oral candidosis in cancer patients. Front Microbiol. 2012 Jun 18;3:220. doi: 10.3389/fmicb.2012.00220.
Mondello F, De Bernardis F, Girolamo A, Salvatore G, Cassone A. In vitro and in vivo activity of tea tree oil against azole-susceptible and-resistant human pathogenic yeasts. J Antimicrob Chemother. 2003 May 1;51(5):1223-9. doi: 10.1093/jac/dkg202.
Wallengren J. Tea tree oil attenuates experimental contact dermatitis. Arch Dermatol Res. 2011 Jul;303(5):333-8. doi: 10.1007/s00403-010-1083-y.
Fang JY, Leu YL, Hwang TL, Cheng HC. Essential oils from sweet basil (Ocimum basilicum) as novel enhancers to accelerate transdermal drug delivery. Biol Pharm Bull. 2004;27(11):1819-25. doi: 10.1248/bpb.27.1819.
Biruss B, Kählig H, Valenta C. Evaluation of an eucalyptus oil containing topical drug delivery system for selected steroid hormones. Int J Pharm. 2007 Jan 10;328(2):142-51. doi: 10.1016/j.ijpharm.2006.08.003.
Rosato A, Vitali C, Gallo D, Balenzano L, Mallamaci R. The inhibition of Candida species by selected essential oils and their synergism with amphotericin B. Phytomedicine. 2008 Aug 1;15(8):635-8. doi: 10.1016/j.phymed.2008.05.001.
Barchiesi F, Silvestri C, Arzeni D, Ganzetti G, Castelletti S, Simonetti O, C, et al. In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. Med Mycol. 2009 May 1;47(3):321-6. doi: 10.1080/13693780802641920.
Misner BD. A novel aromatic oil compound inhibits microbial overgrowth on feet: a case study. JISSN. 2007 Dec;4:1-4. doi: 10.1186/1550-2783-4-3.
Buck DS, Nidorf DM, Addino JG. Comparison of two topical preparations for the treatment of onychomycosis: Melaleuca alternifolia (tea tree) oil and clotrimazole. JFP 1994 Jun 1;38(6):601-6. PMID:8195735.
Flores FC, De Lima JA, Ribeiro RF, Alves SH, Rolim CM, Beck RC, et al. Antifungal activity of nanocapsule suspensions containing tea tree oil on the growth of Trichophyton rubrum. Mycopathologia. 2013 Apr;175:281-6. doi: 10.1007/s11046-013-9622-7.
Romero-Cerecero O, Zamilpa A, Jiménez-Ferrer JE, Rojas-Bribiesca G, Román-Ramos R, Tortoriello J. Double-blind clinical trial for evaluating the effectiveness and tolerability of Ageratina pichinchensis extract on patients with mild to moderate onychomycosis. A comparative study with ciclopirox. Planta Med. 2008 Oct;74(12):1430-5. doi: 10.1055/s-0028-1088372.
Romero-Cerecero O, Román-Ramos R, Zamilpa A, Jiménez-Ferrer JE, Rojas-Bribiesca G, Tortoriello J. Clinical trial to compare the effectiveness of two concentrations of the Ageratina pichinchensis extract in the topical treatment of onychomycosis. J Ethnopharmacol. 2009 Oct 29;126(1):74-8. doi: 10.1016/j.jep.2009.08.007.
Sipponen A, Peltola R, Jokinen JJ, Laitinen K, Lohi J, Rautio M, et al. Effects of Norway spruce (Picea abies) resin on cell wall and cell membrane of Staphylococcus aureus. Ultrastr Pathol. 2009 Jan 1;33(3):128-35. doi: 10.1080/01913120902889138.
Rautio M, Sipponen A, Lohi J, Lounatmaa K, Koukila-Kähkölä P, Laitinen K. In vitro fungistatic effects of natural coniferous resin from Norway spruce (Picea abies). Eur J Clin Microbiol. 2012 Aug;31:1783-9. doi: 10.1007/s10096-011-1502-9.
Rautio M, Sipponen A, Peltola R, Lohi J, Jokinen JJ, Papp A, et al. Antibacterial effects of home‐made resin salve from Norway spruce (Picea abies). Apmis. 2007 Apr;115(4):335-40. doi: 10.1111/j.1600-0463.2007.apm_548.x.
Sipponen A, Laitinen K. Antimicrobial properties of natural coniferous rosin in the European Pharmacopoeia challenge test. Apmis. 2011 Oct;119(10):720-4. doi: 10.1111/j.1600-0463.2011.02791.x.
Sipponen P, Sipponen A, Lohi J, Soini M, Tapanainen R, Jokinen JJ. Natural coniferous resin lacquer in treatment of toenail onychomycosis: an observational study. Mycoses. 2013 May;56(3):289-96. doi: 10.1111/myc.12019.
Malay DS, Yi S, Borowsky P, Downey MS, Mlodzienski AJ. Efficacy of debridement alone versus debridement combined with topical antifungal nail lacquer for the treatment of pedal onychomycosis: a randomized, controlled trial. JFAS. 2009 May 1;48(3):294-308. doi: 10.1053/j.jfas.2008.12.012.
Shemer A, Nathansohn N, Trau H, Amichai B, Grunwald MH. Ciclopirox nail lacquer for the treatment of onychomycosis: an open non‐comparative study. J Dermatol. 2010 Feb;37(2):137-9. doi: 10.1111/j.1346-8138.2009.00773.x.
Kracht T, Müller-Goymann CC. Antifungal efficacy of liquid poloxamer 407-based emulsions loaded with sertaconazole nitrate. Int J Pharm. 2020 Jul 30;585:119400. doi: 10.1016/j.ijpharm.2020.119400.
Choi FD, Juhasz ML, Mesinkovska NA. Topical ketoconazole: a systematic review of current dermatological applications and future developments. J Dermatol Treat. 2019 Feb 14. doi: 10.1080/09546634.2019.1573309.
Silva AP, Chiandrone DJ, Tinta JW, Kurachi C, Inada NM, Bagnato VS. Development and comparison of two devices for treatment of onychomycosis by photodynamic therapy. J Biomed Opt. 2015 Jun 1;20(6):061109. doi: 10.1117/1.JBO.20.6.061109.
Morgado LF, Trávolo AR, Muehlmann LA, Narcizo PS, Nunes RB, Pereira PA, et al. Photodynamic therapy treatment of onychomycosis with Aluminium-Phthalocyanine Chloride nanoemulsions: A proof of concept clinical trial. J Photochem Photobiol Biol. 2017 Aug 1;173:266-70. doi: 10.1016/j.jphotobiol.2017.06.010.
Senge MO. mTHPC–A drug on its way from second to third generation photosensitizer?. PDPDT. 2012 Jun 1;9(2):170-9. doi: 10.1016/j.pdpdt.2011.10.001.
Pape WJ, Pfannenbecker U, Hoppe U. Validation of the red blood cell test system as in vitro assay for the rapid screening of irritation potential of surfactants. Mol Toxicol. 1987 Sep 1;1(4):525-36. PMID: 3509700.
Yang Y, Fang Z, Chen X, Zhang W, Xie Y, Chen Y, et al. An overview of Pickering emulsions: solid-particle materials, classification, morphology, and applications. Front Pharmacol. 2017 May 23;8:235054. doi: 10.3389/fphar.2017.00287.
Chevalier Y, Bolzinger MA. Emulsions stabilized with solid nanoparticles: Pickering emulsions. Colloids Surf A Physicochem Eng. 2013 Dec 20;439:23-34. doi: 10.1016/j.colsurfa.2013.02.054.
Binks BP. Particles as surfactants—similarities and differences. COCIS. 2002 Mar 1;7(1-2):21-41. doi: 10.1016/S1359-0294(02)00008-0.
Vörös-Horváth B, Das S, Salem A, Nagy S, Böszörményi A, Kőszegi T, et al. Formulation of tioconazole and melaleuca alternifolia essential oil pickering emulsions for onychomycosis topical treatment. Molecules. 2020 Nov 26;25(23):5544. doi: 10.3390/molecules25235544.
Agrawal V, Patel R, Patel M, Thanki K, Mishra S. Design and evaluation of microemulsion-based efinaconazole formulations for targeted treatment of onychomycosis through transungual route: Ex vivo and nail clipping studies. Colloid Surf B. 2021 May 1;201:111652. doi: 10.1016/j.colsurfb.2021.111652.
Pal P, Thakur RS, Ray S, Mazumder B. Design and development of a safer non-invasive transungual drug delivery system for topical treatment of onychomycosis. Drug Dev Ind Pharm.2015 Jul 3;41(7):1095-9. doi: 10.3109/03639045.2014.931966.
Souza AM, Ribeiro RC, Pinheiro GK, Pinheiro FI, Oliveira WN, Souza LB, et al. Polishing the therapy of onychomycosis induced by Candida spp.: amphotericin B–loaded nail lacquer. Pharmaceutics. 2021 May 24;13(6):784. doi: 10.3390/pharmaceutics13060784.
Al-Obaidi H, Petraityte I, Hibbard T, Majumder M, Kalgudi R, Zariwala MG. Antifungal nanosuspensions with surfactants and silver for the treatment of onychomycosis. Eur J Pharm Biopharm. 2022 Oct 1;179:194-205. doi: 10.1016/j.ejpb.2022.09.004.
Chopra H, Kumar S, Singh I. Bioadhesive hydrogels and their applications. Bioadhes Drug Deliv. 2020 Jun 1:147-70. doi: 10.1002/9781119640240.ch6.
Chopra H, Bibi S, Kumar S, Khan MS, Kumar P, Singh I. Preparation and evaluation of chitosan/PVA based hydrogel films loaded with honey for wound healing application. Gels. 2022 Feb 11;8(2):111. doi: 10.3390/gels8020111.
Kesharwani P, Fatima M, Singh V, Sheikh A, Almalki WH, Gajbhiye V, et al. Itraconazole and difluorinated-curcumin containing chitosan nanoparticle loaded hydrogel for amelioration of onychomycosis. Biomimetics. 2022 Nov 21;7(4):206. doi: 10.3390/biomimetics7040206.
Amra K, Momin M. Formulation evaluation of ketoconazole microemulsion‐loaded hydrogel with nigella oil as a penetration enhancer. J Cosmet Dermatol. 2019 Dec;18(6):1742-50. doi: 10.1111/jocd.12945.
Puri V, Froelich A, Shah P, Pringle S, Chen K, Michniak-Kohn B. Quality by design guided development of polymeric nanospheres of terbinafine hydrochloride for topical treatment of onychomycosis using a nano-gel formulation. Pharmaceutics. 2022 Oct 12;14(10):2170. doi: 10.3390/pharmaceutics14102170.
Gaballah EY, Borg TM, Mohamed EA. Hydroxypropyl chitosan nail lacquer of ciclopirox-PLGA nanocapsules for augmented in vitro nail plate absorption and onychomycosis treatment. J Drug Deliv. 2022 Dec 31;29(1):3304-16. doi: 10.1080/10717544.2022.2144543.
Flores FC, Rosso RS, Cruz L, Beck RC, Silva CB. An innovative polysaccharide nanobased nail formulation for improvement of onychomycosis treatment. Eur J Pharm Sci. 2017 Mar 30;100:56-63. doi: 10.1016/j.ejps.2016.12.043.
Bsieso EA, Nasr M, Moftah NH, Sammour OA, Abd El Gawad NA. Could nanovesicles containing a penetration enhancer clinically improve the therapeutic outcome in skin fungal diseases?. Nanomedicine. 2015 Jul;10(13):2017-31. doi: 10.2217/nnm.15.49.
Bseiso EA, Nasr M, Sammour OA, Abd El Gawad NA. Novel nail penetration enhancer containing vesicles “nPEVs” for treatment of onychomycosis. J Drug Deliv. 2016 Oct 12;23(8):2813-9. doi: 10.3109/10717544.2015.1099059.
Tuncay Tanrıverdi S, Hilmioğlu Polat S, Yeşim Metin D, Kandiloğlu G, Özer Ö. Terbinafine hydrochloride loaded liposome film formulation for treatment of onychomycosis: in vitro and in vivo evaluation. J Liposome Res. 2016 Apr 2;26(2):163-73. doi: 10.3109/08982104.2015.1067892.
Shah VH, Jobanputra A. Enhanced ungual permeation of terbinafine HCl delivered through liposome-loaded nail lacquer formulation optimized by QbD approach. AAPS Pharm Sci Tech. 2018 Jan;19(1):213-24. doi: 10.1208/s12249-017-0831-0.
Ghannoum M, Isham N, Long L. In vitro antifungal activity of ME1111, a new topical agent for onychomycosis, against clinical isolates of dermatophytes. AAC. 2015 Sep;59(9):5154-8. doi: 10.1128/aac.0092-15.
Murdan S. Drug delivery to the nail following topical application. Int J Pharm 2002 Apr 2;236(1-2):1-26. doi: 10.1016/S0378-5173(01)00989-9.
Tabata Y, Takei-Masuda N, Kubota N, Takahata S, Ohyama M, Kaneda K, et al. Characterization of antifungal activity and nail penetration of ME1111, a new antifungal agent for topical treatment of onychomycosis. Antimicrob Agents Chemother. 2016 Feb;60(2):1035-9. doi: 10.1128/aac.01739-15.
Satyavert, Gupta S, Choudhury H, Jacob S, Nair AB, Dhanawat M, et al. Pharmacokinetics and tissue distribution of hydrazinocurcumin in rats. Pharmacol Rep. 2021 Dec;73:1734-43. doi: 10.1007/s43440-021-00312-5.
Avenot HF, Sellam A, Karaoglanidis G, Michailides TJ. Characterization of mutations in the iron-sulphur subunit of succinate dehydrogenase correlating with boscalid resistance in Alternaria alternata from California pistachio Phytopathol. 2008 Jun;98(6):736-42. doi: 10.1094/PHYTO-98-6-0736.
Shima Y, Ito Y, Kaneko S, Hatabayashi H, Watanabe Y, Adachi Y, et al. Identification of three mutant loci conferring carboxin-resistance and development of a novel transformation system in Aspergillus oryzae. Fungal Genet Biol. 2009 Jan 1;46(1):67-76. doi: 10.1016/j.fgb.2008.10.005.
Sun F, Huo X, Zhai Y, Wang A, Xu J, Su D, Bartlam M, Rao Z. Crystal structure of mitochondrial respiratory membrane protein complex II. Cell. 2005 Jul 1;121(7):1043-57. doi: 10.1016/j.cell.2005.05.025.
Mercer DK, Stewart CS, Miller L, Robertson J, Duncan VM, O’Neil DA. Improved methods for assessing therapeutic potential of antifungal agents against dermatophytes and their application in the development of NP213, a novel onychomycosis therapy candidate. AAC. 2019 May;63(5):10-128. doi: 10.1128/aac.02117-18.
Hancock RE, Haney EF, Gill EE. The immunology of host defence peptides: beyond antimicrobial activity. Nat Rev Immunol.2016 May;16(5):321-34. doi: 10.1038/nri.2016.29.
Haney EF, Straus SK, Hancock RE. Reassessing the host defense peptide landscape. Front Chem. 2019 Feb 4;7:435645. doi: 10.3389/fchem.2019.00043.
Munjal K, Sharma S, Sharma S, Kumar D, Choudhary A, Berwal R, et al. Comparison of serum 25-hydroxyvitamin D levels after a single oral dose of vitamin D3 formulations in mild vitamin D3 deficiency. J Pharmacol Pharmacother. 2021 Dec;12(4):163-7. doi: 10.4103/jpp.jpp_105.
Cutrín-Gómez E, Anguiano-Igea S, Delgado-Charro MB, Gómez-Amoza JL, Otero-Espinar FJ. Effect of penetration enhancers on drug nail permeability from cyclodextrin/poloxamer-soluble polypseudorotaxane-based nail lacquers. Pharmaceutics. 2018 Dec 13;10(4):273. doi: 10.3390/pharmaceutics10040273.
Elsayed MM. Development of topical therapeutics for management of onychomycosis and other nail disorders: a pharmaceutical perspective. JCR. 2015 Feb 10;199:132-44. doi: 10.1016/j.jconrel.2014.11.017.
Brasch J, Kreiselmaier I, Christophers E. Inhibition of dermatophytes by optical brighteners. Mycoses. 2003 Mar 4;46(3‐4):120-5. doi: 10.1046/j.1439-0507.2003.00857.x.
Kingsbury JM, Heitman J, Pinnell SR. Calcofluor white combination antifungal treatments for Trichophyton rubrum and Candida albicans. PLoS One. 2012 Jul 6;7(7):e39405. doi: 10.1371/journal.pone.0039405.
Malik J, Munjal K, Deshmukh R. Attenuating effect of standardized lyophilized Cinnamomum zeylanicum bark extract against streptozotocin-induced experimental dementia of Alzheimer’s type. J Basic Clin Physiol Pharmacol. 2015 May 1;26(3):275-85. doi: 10.1515/jbcpp-2014-0012.
Hafeez F, Hui X, Chiang A, Hornby S, Maibach H. Transungual delivery of ketoconazole using novel lacquer formulation. Int J Pharm. 2013 Nov 18;456(2):357-61. doi: 10.1016/j.ijpharm.2013.08.082.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).